Hemogenyx Pharmaceuticals PLC Announces Final Results
-
NZ internal report warns of Chinese military forays in Pacific
-
Japan to play Brazil in World Cup knockouts after nervy Sweden draw
-
Dutch march into World Cup knockouts as group winners
-
Better to qualify this way, says Ecuador World Cup hero Plata
-
Ivory Coast see 'no limits' after reaching World Cup knockouts for first time
-
Advocaat 'proud' of Curacao as minnows exit World Cup
-
Germany committed 'tactical suicide', says Nagelsmann
-
Iglesias -- Spanish World Cup striker unafraid to speak out about injustice
-
Quake-hit Venezuela's hospitals care for children left alone
-
Anderson to join Man City from Forest for British record fee: reports
-
Cole grabs PGA Travelers lead with Scheffler one back
-
Ecuador upset Germany to reach World Cup last 32 as Curacao eliminated
-
De Silva century rescues Sri Lanka in first Test
-
Ecuador edge Germany to squeeze into World Cup last 32
-
Pepe steers Ivory Coast into World Cup last 32 as Curacao go home
-
Spain women's star Putellas to join London City Lionesses
-
WNBA suspends Thomas for fist to Clark's throat
-
England showing Premier League edge at World Cup: Eze
-
UK'S King Charles breaks precedent to reveal £30 mn paid in taxes since 2022
-
Nasdaq falls again on mixed day for US stocks, oil prices rise
-
Yoon grabs early Women's PGA Championship lead with Korda in hunt
-
France squad look to do grieving Deschamps proud in final World Cup group game
-
Will Taylor Swift and Travis Kelce wed in New York? Clues abound
-
Mayweather's Athens fight with Zambidis is off: report
-
Lawyer says Vondrousova 'should appeal' against four-year ban
-
Alonso committed to Aston Martin, but keeping options open
-
Hospitals raise alert as heatwave slams Europe
-
Events cancelled, records loom as heatwave reaches Germany
-
'Alligator Alcatraz' detention center shuts in US: official
-
Czech striker Schick ends international career
-
Tennis great Evert says 'relentless' cancer has returned
-
US says wants deal with Iran, but not 'at any price'
-
Colombian president-elect gives armed groups one month to surrender
-
US Supreme Court hands win to Bayer in weedkiller litigation
-
New Zealand's Latham and Conway pile on the runs before Stokes breakthrough
-
Apple raises prices for MacBooks and iPads, as costs soar over AI
-
Dominant Osaka sails into Bad Homburg semis
-
UK suffers as heat breaks new June record
-
US Supreme Court says asylum seekers can be turned away before border
-
Binance to suspend crypto services in several EU countries
-
Olivia Wilde looks at evolving relationships in 'The Invite'
-
Hamilton reveals neck injury that hampered debut year with Ferrari
-
Rows, drones and 'sorry' Son as South Korea await World Cup fate
-
Noosha Aubel and Dietmar Woidke: How Potsdam Is Letting Down a Young Child with Profound Disabilities
-
Antonelli welcomes Mercedes upgrade as Russell says beware Hamilton
-
Greek families receive keepsakes of Holocaust victims
-
Antonelli welcomes Mercedes upgrade ast Russell says beware Hamilton
-
Easyjet rejects latest takeover bid but leaves door ajar
-
HRW denounces Turkey arrests ahead of NATO summit
-
Macron hosts Meloni for Riviera talks after Trump rift
Hemogenyx Pharmaceuticals PLC Announces Final Results
LONDON, UNITED KINGDOM / ACCESS Newswire / April 28, 2025 / Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces its final audited results for the year ended 31 December 2024. The Annual Report is available to view on the Company's website at https://hemogenyx.com/.
Key Highlights
The Company commenced Phase I clinical trials of its HG-CT-1 product candidate.
Continuing development of Chimeric Bait Receptor antiviral/biodefence platform, which gained attention at major conferences.
Successfully raised £3.9 million (before expenses) through the allotment and issue of new ordinary shares during the year ended 31 December 2024, and a further £1.3 million in early 2025.
Fuller details of these developments are contained in the full, unedited text of the final results for the year ended 31 December 2024 below.
http://www.rns-pdf.londonstockexchange.com/rns/3187G_1-2025-4-25.pdf
Enquiries:
Hemogenyx Pharmaceuticals plc | |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | |
Peter Redmond, Director | |
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl | |
Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View the original press release on ACCESS Newswire
Th.Gonzalez--AT
